Novartis outlines plan to become a ''top-five player'' in U.S. pharmaceuticals market
Novartis AG on Thursday told investors that the Swiss drug maker plans to adopt a "U.S.-first mindset" in its bid to become a "top-five player" in the U.S. market by 2027. Novartis is one of the world''s largest pharmaceutical companies; however in the U.S., it was the tenth largest by revenue in the U.S. in 2021, according to FiercePharma. Novartis also said it plans to become a "top-three player" in China. U.S.-listed shares of Novartis are down 11.8% this year, while the SP 500 has declined 20.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Novartis outlines plan to become a ''top-five player'' in U.S. pharmaceuticals market
Novartis AG on Thursday told investors that the Swiss drug maker plans to adopt a "U.S.-first mindset" in its bid to become a "top-five player" in the U.S. market by 2027. Novartis is one of the world''s largest pharmaceutical companies; however in the U.S., it was the tenth largest by revenue in the U.S. in 2021, according to FiercePharma. Novartis also said it plans to become a "top-three player" in China. U.S.-listed shares of Novartis are down 11.8% this year, while the SP 500 has declined 20.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.